Biocon reported a consolidated net profit of Rs. 144 crore for the third quarter, reflecting improved operational performance across its biosimilars and generics portfolio. The earnings uptick underscores disciplined cost management, portfolio optimization and steady global demand for specialty pharmaceuticals. Revenue growth was supported by traction in regulated markets and a stable contribution from research services. Despite industry-wide pricing pressures and currency fluctuations, the company maintained margin stability through scale efficiencies and product mix enhancement.